Skip to main content
. 2017 Mar 21;5:23. doi: 10.1186/s40425-017-0228-3

Fig. 2.

Fig. 2

Partial response of metastatic basal cell carcinoma to pembrolizumab (anti-PD-1). Computed tomography (CT) scans performed pre-therapy (top row) and 6.5 months after initiating pembrolizumab (anti-PD-1, bottom row) demonstrate regression of basal cell carcinoma lung metastases. Yellow arrowheads indicate sites of metastases